INCY SEC filings (2026)
CIK 879169 · Services-Commercial Physical & Biological Research (SIC 8731) · incorporated in DE · fiscal year ends in December
2,616 filings on EDGAR since 1994 · 35 annual, 94 quarterly, 278 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
September 2026
August 2026
- Aug 318-K8-K · Other events
- Aug 19Insider saleCAGNONI PABLO J (President, Global Head of R&D) sold 10,801 shares for $1.4M at $125.56 under a 10b5-1 plan
- Aug 12Insider saleCAGNONI PABLO J (President, Global Head of R&D) sold 10,803 shares for $1.3M at $120.04 under a 10b5-1 plan
- Aug 5Insider saleCAGNONI PABLO J (President, Global Head of R&D) sold 10,640 shares for $1.3M at $122.69 under a 10b5-1 plan
- Aug 5Insider saleMayes Patrick A (EVP & Chief Scientific Officer) sold 2,207 shares for $274K at $123.99 under a 10b5-1 plan
- Aug 3Insider saleMayes Patrick A (EVP & Chief Scientific Officer) sold 6,055 shares for $729K at $120.43 under a 10b5-1 plan
July 2026
- Jul 31Insider saleMayes Patrick A (EVP & Chief Scientific Officer) sold 41,899 shares for $5.0M at $119.38–$122.19 under a 10b5-1 plan
- Jul 31Insider saleCAGNONI PABLO J (President, Global Head of R&D) sold 15,888 shares for $1.9M at $119.70 under a 10b5-1 plan
- Jul 28EarningsEarnings release — EPS $2.80 vs $1.76 est. (+59.1%); revenue $1.67B (+38% y/y) 9.3%
- Jul 28ReportQuarterly report, Q2 2026 — revenue $1.67B (+38% y/y), net income $585.6M, EPS $2.81
- Jul 16Insider saleStein Steven H (CMO & Head of Late-Stage Dev.) sold 1,877 shares for $215K at $114.73 under a 10b5-1 plan
- Jul 16Insider saleIssa Mohamed Khairie (EVP, Head of U.S. Commercial) sold 1,093 shares for $126K at $115.01 under a 10b5-1 plan
- Jul 15Insider saleStein Steven H (CMO & Head of Late-Stage Dev.) sold 28,237 shares for $3.2M at $113.05 under a 10b5-1 plan
- Jul 68-K8-K · Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioOther events
June 2026
- Jun 228-K8-K · Other events
- Jun 98-K8-K · Shareholder vote results
- Jun 88-K8-K · Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding DisordersOther events
- Jun 4Insider saleTray Thomas (Principal Accounting Officer) sold 2,639 shares for $264K at $100.00 under a 10b5-1 plan
May 2026
- May 27ProxyProxy · Additional proxy materials
- May 26Insider saleTray Thomas (Principal Accounting Officer) sold 2,051 shares for $200K at $97.35 under a 10b5-1 plan
- May 19Insider saleClancy Paul J (Director) sold 15,000 shares for $1.4M at $94.93 under a 10b5-1 plan
April 2026
- Apr 28EarningsEarnings release — EPS $1.55 vs $1.14 est. (+36.0%); revenue $1.27B (+21% y/y) 2.1%
- Apr 28ReportQuarterly report, Q1 2026 — revenue $1.27B (+21% y/y), net income $303.3M, EPS $1.47
- Apr 28ProxyProxy · Annual report to shareholders
- Apr 28ProxyProxy · Additional proxy materials
- Apr 28ProxyProxy · Proxy statement
- Apr 17Insider saleCAGNONI PABLO J (President, Global Head of R&D) sold 18,667 shares for $1.8M at $96.50 under a 10b5-1 plan
March 2026
- Mar 308-K8-K · Directors or officers; compensation
- Mar 268-K8-K · Incyte Announces Executive Leadership AppointmentsDirectors or officers; compensation
- Mar 17Insider saleCAGNONI PABLO J (President, R&D) sold 18,667 shares for $1.8M at $94.24 under a 10b5-1 plan
- Mar 68-K8-K · Other events
February 2026
January 2026
December 2025
- Dec 128-K8-K · Directors or officers; compensation
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $298K · 2,642 sh · 10b5-1 |
| Sep 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $2.8M · 23,218 sh · 10b5-1 |
| Aug 19, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $1.4M · 10,801 sh · 10b5-1 |
| Aug 12, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $1.3M · 10,803 sh · 10b5-1 |
| Aug 5, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $1.3M · 10,640 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerSold · $274K · 2,207 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerSold · $729K · 6,055 sh · 10b5-1 |
| Jul 31, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerSold · $5.0M · 41,899 sh · 10b5-1 |
| Jul 31, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $1.9M · 15,888 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Sold · $215K · 1,877 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Issa Mohamed KhairieEVP, Head of U.S. CommercialSold · $126K · 1,093 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Sold · $3.2M · 28,237 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerSold · $264K · 2,639 sh · 10b5-1 |
| May 26, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerSold · $200K · 2,051 sh · 10b5-1 |
| May 19, 2026Form 4 | Clancy Paul JDirectorSold · $1.4M · 15,000 sh · 10b5-1 |
| Apr 17, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DSold · $1.8M · 18,667 sh · 10b5-1 |
| Mar 17, 2026Form 4 | CAGNONI PABLO JPresident, R&DSold · $1.8M · 18,667 sh · 10b5-1 |
| Feb 19, 2026Form 4 | CAGNONI PABLO JPresident, R&DSold · $1.9M · 18,668 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Issa Mohamed KhairieEVP, Head of US OncologySold · $1.2M · 10,856 sh · 10b5-1 |
| Jan 5, 2026Form 4 | Stein Steven HEVP & Chief Medical OfficerSold · $1.6M · 15,634 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 121 transactions
| Date | Insider |
|---|---|
| Oct 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $174K · 2,642 sh · 10b5-1 |
| Oct 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 2,642 sh · 10b5-1 |
| Oct 1, 2026Form 4 | Heeson LeeEVP, Head of Incyte IntlTax withholding · $54K · 463 sh |
| Sep 30, 2026Form 4 | HARRIGAN EDMUNDDirectorAward · $25K · 206 sh |
| Sep 30, 2026Form 4 | Clancy Paul JDirectorAward · $25K · 203 sh |
| Sep 30, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 644 sh |
| Sep 22, 2026Form 4 | Gardner David HEVP, Chief Strategy OfficerTax withholding · $117K · 920 sh |
| Sep 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $1.5M · 23,218 sh · 10b5-1 |
| Sep 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 23,218 sh · 10b5-1 |
| Aug 25, 2026Form 4 | Basi Ramitpal KEVP, Human ResourcesTax withholding · $65K · 504 sh |
| Aug 5, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $235K · 2,207 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 2,207 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $638K · 6,055 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 6,055 sh · 10b5-1 |
| Jul 31, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $3.0M · 39,712 sh · 10b5-1 |
| Jul 31, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 39,712 sh · 10b5-1 |
| Jul 23, 2026Form 4 | Heeson LeeEVP, Head of Incyte IntlAward · Employee Stock Option (rig… · $0 · 15,423 sh |
| Jul 23, 2026Form 4 | Heeson LeeEVP, Head of Incyte IntlAward · $0 · 13,498 sh |
| Jul 23, 2026Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsAward · $0 · 8,999 sh |
| Jul 23, 2026Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsAward · Employee Stock Option (rig… · $0 · 6,426 sh |
| Jul 16, 2026Form 4 | Meury WilliamChief Executive Officer · DirectorAward · $0 · 80,421 sh |
| Jul 16, 2026Form 4 | Meury WilliamChief Executive Officer · DirectorAward · Employee Stock Option (rig… · $0 · 77,148 sh |
| Jul 16, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DAward · Employee Stock Option (rig… · $0 · 57,861 sh |
| Jul 16, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Award · Employee Stock Option (rig… · $0 · 42,298 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · Employee Stock Option (rig… · $0 · 33,918 sh · 10b5-1 |
| Jul 16, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 33,508 sh |
| Jul 16, 2026Form 4 | Gardner David HEVP, Chief Strategy OfficerAward · Employee Stock Option (rig… · $0 · 31,923 sh |
| Jul 16, 2026Form 4 | Hoffman Richard A.EVP & General CounselAward · Employee Stock Option (rig… · $0 · 31,923 sh |
| Jul 16, 2026Form 4 | Meury WilliamChief Executive Officer · DirectorAward · $0 · 26,807 sh |
| Jul 16, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerAward · Employee Stock Option (rig… · $0 · 25,538 sh |
| Jul 16, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 24,496 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Basi Ramitpal KEVP, Human ResourcesAward · Employee Stock Option (rig… · $0 · 21,548 sh |
| Jul 16, 2026Form 4 | Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · $0 · 19,643 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Gardner David HEVP, Chief Strategy OfficerAward · $0 · 18,487 sh |
| Jul 16, 2026Form 4 | Hoffman Richard A.EVP & General CounselAward · $0 · 18,487 sh |
| Jul 16, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerAward · $0 · 14,790 sh |
| Jul 16, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 13,403 sh |
| Jul 16, 2026Form 4 | Basi Ramitpal KEVP, Human ResourcesAward · $0 · 12,479 sh |
| Jul 16, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 9,798 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · $0 · 7,857 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Gardner David HEVP, Chief Strategy OfficerAward · $0 · 7,395 sh |
| Jul 16, 2026Form 4 | Hoffman Richard A.EVP & General CounselAward · $0 · 7,395 sh |
| Jul 16, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerAward · $0 · 5,916 sh |
| Jul 16, 2026Form 4 | Basi Ramitpal KEVP, Human ResourcesAward · $0 · 4,991 sh |
| Jul 16, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerAward · Employee Stock Option (rig… · $0 · 4,079 sh |
| Jul 16, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerAward · $0 · 2,834 sh |
| Jul 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $570K · 4,950 sh |
| Jul 15, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $355K · 3,088 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $174K · 1,512 sh |
| Jul 15, 2026Form 4 | Issa Mohamed KhairieEVP, Head of U.S. CommercialTax withholding · $126K · 1,099 sh |
| Jul 15, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerTax withholding · $126K · 1,098 sh |
| Jul 14, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $2.5M · 21,830 sh · 10b5-1 |
| Jul 14, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $2.1M · 17,969 sh |
| Jul 14, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerTax withholding · $79K · 692 sh |
| Jul 14, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $50K · 437 sh |
| Jul 2, 2026Form 4 | Meury WilliamChief Executive Officer · Director · PresidentTax withholding · $558K · 4,779 sh |
| Jul 2, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $254K · 2,177 sh |
| Jul 2, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerTax withholding · $56K · 477 sh |
| Jul 2, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $41K · 350 sh |
| Jun 30, 2026Form 4 | HARRIGAN EDMUNDDirectorAward · $29K · 255 sh |
| Jun 30, 2026Form 4 | Clancy Paul JDirectorAward · $29K · 252 sh |
| Jun 30, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 800 sh |
| Jun 8, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · Non-Qualified Stock Option… · $0 · 12,222 sh |
| Jun 8, 2026Form 4 | HARRIGAN EDMUNDDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | BRAWLEY OTIS WDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | BIENAIME JEAN JACQUESDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | FOUSE JACQUALYN ADirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | Clancy Paul JDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | High Katherine ADirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh |
| Jun 8, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 3,284 sh |
| Jun 8, 2026Form 4 | HARRIGAN EDMUNDDirectorAward · $0 · 1,642 sh |
| Jun 8, 2026Form 4 | BRAWLEY OTIS WDirectorAward · $0 · 1,642 sh |
| Jun 8, 2026Form 4 | BIENAIME JEAN JACQUESDirectorAward · $0 · 1,642 sh |
| Jun 8, 2026Form 4 | FOUSE JACQUALYN ADirectorAward · $0 · 1,642 sh |
| Jun 8, 2026Form 4 | Clancy Paul JDirectorAward · $0 · 1,642 sh |
| Jun 8, 2026Form 4 | High Katherine ADirectorAward · $0 · 1,642 sh |
| Jun 4, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerExercise or conversion · $221K · 2,639 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerExercise or conversion · Non-Qualified Stock Option… · $0 · 2,639 sh · 10b5-1 |
| Jun 1, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $2.4M · 25,469 sh |
| May 26, 2026Form 4 | BIENAIME JEAN JACQUESDirectorTax withholding · $1.3M · 13,059 sh · 10b5-1 |
| May 26, 2026Form 4 | BIENAIME JEAN JACQUESDirectorExercise or conversion · $1.3M · 15,000 sh · 10b5-1 |
| May 26, 2026Form 4 | BIENAIME JEAN JACQUESDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 15,000 sh · 10b5-1 |
| May 19, 2026Form 4 | Clancy Paul JDirectorExercise or conversion · $1.3M · 15,000 sh · 10b5-1 |
| May 19, 2026Form 4 | Clancy Paul JDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 15,000 sh · 10b5-1 |
| May 8, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · $2.5M · 30,000 sh |
| May 8, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · Non-Qualified Stock Options · $0 · 30,000 sh |
| May 6, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 44,124 sh |
| May 6, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 31,517 sh |
| May 4, 2026Form 4 | Upadhyay SuketuEVP & Chief Financial OfficerAward · Employee Stock Option (rig… · $0 · 38,429 sh |
| May 4, 2026Form 4 | Upadhyay SuketuEVP & Chief Financial OfficerAward · $0 · 26,343 sh |
| May 4, 2026Form 4 | Upadhyay SuketuEVP & Chief Financial OfficerAward · $0 · 13,171 sh |
| Apr 17, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $1.3M · 18,667 sh · 10b5-1 |
| Apr 17, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,667 sh · 10b5-1 |
| Apr 15, 2026Form 4 | Meury WilliamChief Executive Officer · Director · PresidentExercise or conversion · $0 · 125,000 sh |
| Apr 15, 2026Form 4 | Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 39,049 sh |
| Apr 15, 2026Form 4 | CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 27,892 sh |
| Mar 31, 2026Form 4 | HARRIGAN EDMUNDDirectorAward · $25K · 269 sh |
| Mar 31, 2026Form 4 | Clancy Paul JDirectorAward · $25K · 265 sh |
| Mar 31, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 842 sh |
| Mar 25, 2026Form 4 | Trotta MatteoEVP, GM, Dermatology USTax withholding · $50K · 537 sh |
| Mar 17, 2026Form 4 | CAGNONI PABLO JPresident, R&DExercise or conversion · $1.2M · 18,667 sh · 10b5-1 |
| Mar 17, 2026Form 4 | CAGNONI PABLO JPresident, R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,667 sh · 10b5-1 |
| Feb 19, 2026Form 4 | CAGNONI PABLO JPresident, R&DExercise or conversion · $1.1M · 18,668 sh · 10b5-1 |
| Feb 19, 2026Form 4 | CAGNONI PABLO JPresident, R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,668 sh · 10b5-1 |
| Feb 2, 2026Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $19K · 185 sh |
| Feb 2, 2026Form 4 | Heeson LeeEVP, Head of Incyte IntlTax withholding · $11K · 111 sh |
| Jan 20, 2026Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $44K · 429 sh |
| Jan 16, 2026Form 4 | CAGNONI PABLO JPresident, R&DAward · Employee Stock Option (rig… · $0 · 28,475 sh |
| Jan 16, 2026Form 4 | Stein Steven HEVP & Chief Medical OfficerAward · Employee Stock Option (rig… · $0 · 19,932 sh |
| Jan 16, 2026Form 4 | Issa Mohamed KhairieEVP, Head of US OncologyAward · Employee Stock Option (rig… · $0 · 14,237 sh |
| Jan 16, 2026Form 4 | Heeson LeeEVP, Head of Incyte IntlAward · $0 · 8,911 sh |
| Jan 16, 2026Form 4 | Trotta MatteoEVP, GM, Dermatology USAward · Employee Stock Option (rig… · $0 · 8,542 sh |
| Jan 16, 2026Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsAward · $0 · 7,426 sh |
| Jan 16, 2026Form 4 | Mayes Patrick AEVP & Chief Scientific OfficerAward · Employee Stock Option (rig… · $0 · 4,218 sh |
| Jan 16, 2026Form 4 | Tray ThomasPrincipal Accounting OfficerAward · Employee Stock Option (rig… · $0 · 2,425 sh |
| Jan 6, 2026Form 4 | Issa Mohamed KhairieEVP, Head of US OncologyTax withholding · $881K · 8,264 sh · 10b5-1 |
| Dec 31, 2025Form 4 | Stein Steven HEVP & Chief Medical OfficerTax withholding · $1.3M · 13,292 sh |
| Dec 31, 2025Form 4 | Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $25K · 254 sh |
| Dec 31, 2025Form 4 | HARRIGAN EDMUNDDirectorAward · $24K · 245 sh |
| Dec 31, 2025Form 4 | Clancy Paul JDirectorAward · $24K · 241 sh |
| Dec 31, 2025Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 656 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 18 filings
| Filed | What it is |
|---|---|
| Aug 31, 20268-K | Other events |
| Jul 28, 202610-Q | Quarterly report, Q2 2026 — revenue $1.67B (+38% y/y), net income $585.6M, EPS $2.81 |
| Jul 28, 20268-K | Earnings release — EPS $2.80 vs $1.76 est. (+59.1%); revenue $1.67B (+38% y/y) 9.3% |
| Jul 6, 20268-K | Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioOther events |
| Jun 22, 20268-K | Other events |
| Jun 9, 20268-K | Shareholder vote results |
| Jun 8, 20268-K | Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding DisordersOther events |
| May 27, 2026DEFA14A | Additional proxy materials |
| Apr 28, 2026ARS | Annual report to shareholders |
| Apr 28, 2026DEFA14A | Additional proxy materials |
| Apr 28, 2026DEF 14A | Proxy statement |
| Apr 28, 202610-Q | Quarterly report, Q1 2026 — revenue $1.27B (+21% y/y), net income $303.3M, EPS $1.47 |
| Apr 28, 20268-K | Earnings release — EPS $1.55 vs $1.14 est. (+36.0%); revenue $1.27B (+21% y/y) 2.1% |
| Mar 30, 20268-K | Directors or officers; compensation |
| Mar 26, 20268-K | Incyte Announces Executive Leadership AppointmentsDirectors or officers; compensation |
| Mar 6, 20268-K | Other events |
| Feb 10, 202610-K | Annual report, FY2025 — revenue $5.14B (+21% y/y), net income $1.29B, EPS $6.41 |
| Feb 10, 20268-K | Earnings release — EPS $1.56 vs $1.64 est. (−4.9%); revenue $1.51B (+28% y/y) 8.2% |
2025 · 18 filings
| Filed | What it is |
|---|---|
| Dec 12, 20258-K | Directors or officers; compensation |
| Oct 28, 202510-Q | Quarterly report, Q3 2025 — revenue $1.37B (+20% y/y), net income $424.2M, EPS $2.11 |
| Oct 28, 20258-K | Earnings release — EPS $2.03 vs $1.38 est. (+47.1%); revenue $1.37B (+20% y/y) 1.5% |
| Oct 3, 20258-K | Directors or officers; compensation |
| Aug 7, 20258-K | Directors or officers; compensation |
| Jul 29, 202510-Q | Quarterly report, Q2 2025 — revenue $1.22B (+16% y/y), net income $405.0M, EPS $2.04 |
| Jul 29, 20258-K | Earnings release — EPS $1.31 vs $1.14 est. (+14.9%); revenue $1.22B (+16% y/y) 10.3% |
| Jun 27, 20258-K | Directors or officers; compensation |
| Jun 11, 20258-K | Directors or officers; compensation; Shareholder vote results |
| May 14, 20258-K | Other events |
| Apr 29, 2025ARS | Annual report to shareholders |
| Apr 29, 2025DEFA14A | Additional proxy materials |
| Apr 29, 2025DEF 14A | Proxy statement |
| Apr 29, 202510-Q | Quarterly report, Q1 2025 — revenue $1.05B (+20% y/y), net income $158.2M, EPS $0.80 |
| Apr 29, 20258-K | Earnings release — EPS $0.89 vs $0.75 est. (+18.7%); revenue $1.05B (+20% y/y) 1.5% |
| Feb 10, 202510-K | Annual report, FY2024 — revenue $4.24B (+15% y/y), net income $32.6M, EPS $0.15 |
| Feb 10, 20258-K | Earnings release — EPS $1.09 vs $1.29 est. (−15.5%); revenue $1.18B (+16% y/y) 7.9% |
| Jan 10, 20258-K | Directors or officers; compensation |
2024 · 16 filings
| Filed | What it is |
|---|---|
| Oct 29, 202410-Q | Quarterly report, Q3 2024 — revenue $1.14B (+24% y/y), net income $106.5M, EPS $0.54 |
| Oct 29, 20248-K | Earnings release — EPS $0.73 vs $0.88 est. (−17.1%); revenue $1.14B (+24% y/y) 12.0% |
| Jul 30, 202410-Q | Quarterly report, Q2 2024 — revenue $1.04B (+9% y/y), net income −$444.6M, EPS −$2.04 |
| Jul 30, 20248-K | Earnings release — EPS −$2.03 vs $0.59 est. (−444.1%); revenue $1.04B (+9% y/y) 1.2% |
| Jul 3, 20248-K | Material definitive agreement; New financial obligation |
| Jun 14, 20248-K | Shareholder vote results |
| May 30, 2024DEFA14A | Additional proxy materials |
| May 13, 20248-K | Material definitive agreement; Regulation FD disclosure |
| Apr 30, 202410-Q | Quarterly report, Q1 2024 — revenue $880.9M (+9% y/y), net income $169.5M, EPS $0.75 |
| Apr 30, 20248-K | Earnings release — EPS $0.38 vs $0.69 est. (−44.9%); revenue $880.9M (+9% y/y) 1.0% |
| Apr 29, 2024ARS | Annual report to shareholders |
| Apr 29, 2024DEFA14A | Additional proxy materials |
| Apr 29, 2024DEF 14A | Proxy statement |
| Feb 16, 202410-K/A | Annual report, amended |
| Feb 13, 202410-K | Annual report, FY2023 — revenue $3.70B (+9% y/y), net income $597.6M, EPS $2.65 |
| Feb 13, 20248-K | Earnings release — EPS $0.82 vs $1.04 est. (−21.1%); revenue $1.01B (+9% y/y) 2.6% |
2023 · 15 filings — 7 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 31, 202310-Q | Quarterly report, Q3 2023 — revenue $919.0M (+12% y/y), net income $171.3M, EPS $0.76 |
| Aug 1, 202310-Q | Quarterly report, Q2 2023 — revenue $954.6M (+5% y/y), net income $203.5M, EPS $0.90 |
| Jun 7, 2023DEFA14A | Additional proxy materials |
| May 2, 202310-Q | Quarterly report, Q1 2023 — revenue $808.7M (+10% y/y), net income $21.7M, EPS $0.10 |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023ARS | Annual report to shareholders |
| Apr 28, 2023DEF 14A | Proxy statement |
| Feb 7, 202310-K | Annual report, FY2022 — revenue $3.39B (+14% y/y), net income $340.7M, EPS $1.52 |
7 current reports (8-K) not listed; the year is on EDGAR.
2022 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 1, 202210-Q | Quarterly report, Q3 2022 — revenue $823.3M (+1% y/y), net income $112.8M, EPS $0.50 |
| Aug 2, 202210-Q | Quarterly report, Q2 2022 — revenue $911.4M (+29% y/y), net income $161.4M, EPS $0.72 |
| May 3, 202210-Q | Quarterly report, Q1 2022 — revenue $733.2M (+21% y/y), net income $38.0M, EPS $0.17 |
| Apr 29, 2022DEFA14A | Additional proxy materials |
| Apr 29, 2022DEF 14A | Proxy statement |
| Feb 8, 202210-K | Annual report, FY2021 — revenue $2.99B (+12% y/y), net income $948.6M, EPS $4.27 |
8 current reports (8-K) not listed; the year is on EDGAR.
2021 · 16 filings — 9 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202110-Q | Quarterly report, Q3 2021 — revenue $813.0M, net income $181.7M, EPS $0.82 |
| Aug 3, 202110-Q | Quarterly report, Q2 2021 — revenue $705.7M (+3% y/y), net income $149.5M, EPS $0.67 |
| May 14, 2021DEFA14A | Additional proxy materials |
| May 4, 202110-Q | Quarterly report, Q1 2021 — revenue $604.7M (+6% y/y), net income $53.5M, EPS $0.24 |
| Apr 16, 2021DEFA14A | Additional proxy materials |
| Apr 16, 2021DEF 14A | Proxy statement |
| Feb 9, 202110-K | Annual report, FY2020 — revenue $2.67B (+24% y/y), net income −$295.7M, EPS −$1.36 |
9 current reports (8-K) not listed; the year is on EDGAR.
2020 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 5, 202010-Q | Quarterly report |
| Aug 4, 202010-Q | Quarterly report, Q2 2020 — revenue $688.0M (+30% y/y), net income $290.3M, EPS $1.32 |
| May 14, 2020DEFA14A | Additional proxy materials |
| May 5, 202010-Q | Quarterly report, Q1 2020 — revenue $568.5M (+14% y/y), net income −$720.6M, EPS −$3.33 |
| Apr 24, 2020PX14A6G | Shareholder exempt solicitation |
| Apr 20, 2020DEF 14A | Proxy statement |
| Feb 13, 202010-K | Annual report, FY2019 — revenue $2.16B (+15% y/y), net income $446.9M, EPS $2.05 |
9 current reports (8-K) not listed; the year is on EDGAR.
2019 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 29, 201910-Q | Quarterly report, Q3 2019 — revenue $551.6M (+23% y/y), net income $128.3M, EPS $0.59 |
| Jul 30, 201910-Q | Quarterly report, Q2 2019 — revenue $529.9M (+2% y/y), net income $105.3M, EPS $0.48 |
| Apr 30, 201910-Q | Quarterly report, Q1 2019 — revenue $497.9M (+30% y/y), net income $102.3M, EPS $0.47 |
| Apr 22, 2019DEFA14A | Additional proxy materials |
| Apr 1, 2019PX14A6G | Shareholder exempt solicitation |
| Mar 21, 2019DEF 14A | Proxy statement |
| Feb 14, 201910-K | Annual report, FY2018 — revenue $1.88B (+23% y/y), net income $109.5M, EPS $0.51 |
7 current reports (8-K) not listed; the year is on EDGAR.
2018 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Oct 30, 201810-Q | Quarterly report, Q3 2018 — revenue $449.7M (+18% y/y), net income $29.2M, EPS $0.14 |
| Jul 31, 201810-Q | Quarterly report, Q2 2018 — revenue $521.5M (+60% y/y), net income $52.4M, EPS $0.24 |
| May 1, 201810-Q | Quarterly report, Q1 2018 — revenue $382.3M (−0% y/y), net income −$41.1M, EPS −$0.19 |
| Mar 14, 2018DEF 14A | Proxy statement |
| Feb 15, 201810-K | Annual report, FY2017 — revenue $1.54B (+39% y/y), net income −$313.1M, EPS −$1.53 |
8 current reports (8-K) not listed; the year is on EDGAR.
2017 · 22 filings — 13 × 8-K, 3 × 10-Q, 2 × 10-K/A and 4 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201710-Q | Quarterly report, Q3 2017 — revenue $381.5M (+42% y/y), net income $36.1M, EPS $0.17 |
| Aug 1, 201710-Q | Quarterly report, Q2 2017 — revenue $326.4M (+33% y/y), net income −$12.5M, EPS −$0.06 |
| Jun 30, 201710-K/A | Annual report, amended |
| May 4, 201710-Q | Quarterly report, Q1 2017 — revenue $384.1M (+46% y/y), net income −$187.1M, EPS −$0.96 |
| Apr 17, 2017DEF 14A | Proxy statement |
| Mar 17, 201710-K/A | Annual report, amended |
| Feb 14, 201710-K | Annual report, FY2016 — revenue $1.11B (+47% y/y), net income $104.2M, EPS $0.54 |
| Feb 14, 201710-Q/A | Quarterly report, amended |
14 current reports (8-K) not listed; the year is on EDGAR.
2016 · 21 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2014 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 18 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2012 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2011 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2010 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 24 filings — 16 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2008 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2007 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2005 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2003 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2002 · 9 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 13 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2000 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
1999 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form
Counted, not listed; the year is on EDGAR.
1998 · 15 filings — 6 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms
Counted, not listed; the year is on EDGAR.
1997 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A and 1 other form
Counted, not listed; the year is on EDGAR.
1996 · 4 filings — 3 × 10-Q, 1 × 8-K
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 109 filings — 78 × 4, 23 × 144, 2 × 4/A and 4 other forms
| Filed | What it is |
|---|---|
| Oct 19, 20264 | Insider transaction (Form 4) |
| Oct 15, 2026144 | Notice of proposed sale (Form 144) |
| Oct 5, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Sep 24, 20264 | Insider transaction (Form 4) |
| Sep 17, 20264 | Insider transaction (Form 4) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Aug 27, 20264 | Insider transaction (Form 4) |
| Aug 20, 20264 | Insider transaction (Form 4) |
| Aug 19, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 20264 | Insider transaction (Form 4) |
| Aug 12, 2026144 | Notice of proposed sale (Form 144) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 5, 2026144 | Notice of proposed sale (Form 144) |
| Aug 5, 2026144 | Notice of proposed sale (Form 144) |
| Aug 4, 20264 | Insider transaction (Form 4) |
| Aug 4, 20264 | Insider transaction (Form 4) |
| Aug 3, 2026144 | Notice of proposed sale (Form 144) |
| Jul 31, 2026144 | Notice of proposed sale (Form 144) |
| Jul 31, 2026144 | Notice of proposed sale (Form 144) |
| Jul 27, 20264 | Insider transaction (Form 4) |
| Jul 27, 20264 | Insider transaction (Form 4) |
The newest 25 of 109 shown; the full year is on EDGAR.
2025 · 167 filings — 102 × 4, 52 × 144, 6 × 3 and 4 other forms
| Filed | What it is |
|---|---|
| Dec 22, 20254 | Insider transaction (Form 4) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 18, 2025144 | Notice of proposed sale (Form 144) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 17, 2025144 | Notice of proposed sale (Form 144) |
| Dec 16, 2025144 | Notice of proposed sale (Form 144) |
| Dec 16, 2025144 | Notice of proposed sale (Form 144) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 20254 | Insider transaction (Form 4) |
| Dec 11, 2025144 | Notice of proposed sale (Form 144) |
| Dec 10, 2025144 | Notice of proposed sale (Form 144) |
| Dec 10, 20254 | Insider transaction (Form 4) |
| Dec 10, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20253 | Initial insider holdings (Form 3) |
| Dec 2, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Nov 25, 20254 | Insider transaction (Form 4) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 21, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 167 shown; the full year is on EDGAR.
2024 · 109 filings — 77 × 4, 12 × 144, 4 × SC 13G and 7 other forms
| Filed | What it is |
|---|---|
| Dec 17, 20244 | Insider transaction (Form 4) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 3, 20244 | Insider transaction (Form 4) |
| Nov 29, 2024144 | Notice of proposed sale (Form 144) |
| Nov 8, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 6, 2024144 | Notice of proposed sale (Form 144) |
| Oct 21, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Oct 17, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Oct 4, 20244 | Insider transaction (Form 4) |
| Oct 3, 20244 | Insider transaction (Form 4) |
| Oct 3, 20243 | Initial insider holdings (Form 3) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Sep 16, 20244 | Insider transaction (Form 4) |
| Sep 16, 20244 | Insider transaction (Form 4) |
| Sep 13, 2024144 | Notice of proposed sale (Form 144) |
| Sep 12, 2024144 | Notice of proposed sale (Form 144) |
| Aug 14, 20244 | Insider transaction (Form 4) |
| Aug 12, 2024144 | Notice of proposed sale (Form 144) |
| Jul 29, 20244 | Insider transaction (Form 4) |
| Jul 25, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 109 shown; the full year is on EDGAR.
2023 · 86 filings — 70 × 4, 6 × SC 13G/A, 3 × 144 and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 87 filings — 76 × 4, 5 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2021 · 106 filings — 96 × 4, 6 × SC 13G/A, 2 × SC 13D/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2020 · 147 filings — 133 × 4, 5 × SC 13G/A, 2 × SEC STAFF LETTER and 6 other forms
Counted, not listed; the year is on EDGAR.
2019 · 132 filings — 111 × 4, 5 × 3, 5 × CT ORDER and 7 other forms
Counted, not listed; the year is on EDGAR.
2018 · 93 filings — 78 × 4, 5 × SC 13G/A, 2 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2017 · 114 filings — 96 × 4, 6 × SC 13G/A, 3 × CT ORDER and 6 other forms
Counted, not listed; the year is on EDGAR.
2016 · 75 filings — 58 × 4, 8 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2015 · 107 filings — 93 × 4, 4 × 3, 4 × SC 13G and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 79 filings — 54 × 4, 6 × SC 13G/A, 5 × 3 and 7 other forms
Counted, not listed; the year is on EDGAR.
2013 · 52 filings — 37 × 4, 4 × 3, 4 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2012 · 55 filings — 37 × 4, 4 × 3, 4 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2011 · 61 filings — 45 × 4, 8 × SC 13G/A, 2 × S-8 and 5 other forms
Counted, not listed; the year is on EDGAR.
2010 · 65 filings — 47 × 4, 7 × SC 13G/A, 2 × CT ORDER and 6 other forms
Counted, not listed; the year is on EDGAR.
2009 · 63 filings — 32 × 4, 8 × SC 13G/A, 4 × SC 13D/A and 12 other forms
Counted, not listed; the year is on EDGAR.
2008 · 89 filings — 55 × 4, 7 × 4/A, 5 × SC 13G and 12 other forms
Counted, not listed; the year is on EDGAR.
2007 · 82 filings — 60 × 4, 8 × 424B7, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2006 · 37 filings — 22 × 4, 3 × 3, 3 × SC 13G and 7 other forms
Counted, not listed; the year is on EDGAR.
2005 · 31 filings — 19 × 4, 4 × SC 13G, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2004 · 82 filings — 53 × 4, 11 × 4/A, 4 × POS AM and 9 other forms
Counted, not listed; the year is on EDGAR.
2003 · 20 filings — 7 × 4, 4 × SC 13G/A, 3 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2002 · 11 filings — 5 × SC 13G/A, 3 × S-8, 1 × POS AM and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 23 filings — 11 × 424B3, 4 × SC 13G/A, 3 × S-8 and 3 other forms
Counted, not listed; the year is on EDGAR.
2000 · 28 filings — 15 × 424B3, 4 × SC 13G/A, 3 × S-3/A and 3 other forms
Counted, not listed; the year is on EDGAR.
1999 · 8 filings — 3 × SC 13G/A, 1 × 424B3, 1 × POS AM and 3 other forms
Counted, not listed; the year is on EDGAR.
1998 · 13 filings — 4 × SC 13G/A, 3 × S-8, 2 × SC 13G and 4 other forms
Counted, not listed; the year is on EDGAR.
1997 · 8 filings — 2 × S-8, 2 × SC 13G/A, 1 × 424B4 and 3 other forms
Counted, not listed; the year is on EDGAR.
1996 · 5 filings — 2 × SC 13G, 1 × 424B4, 1 × S-3 and 1 other form
Counted, not listed; the year is on EDGAR.
1995 · 1 filing — 1 × SC 13G/A
Counted, not listed; the year is on EDGAR.
1994 · 2 filings — 1 × SC 13G, 1 × SC 13G/A
Counted, not listed; the year is on EDGAR.
About this data#
Incyte Corp. (INCY) has 2,616 filings on EDGAR going back to 1994: 35 annual reports, 94 quarterly reports and 278 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 10, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 31, 2026, covered other events. Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Incyte Corp., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read INCY's latest 10-K?
- INCY's latest annual report, a 10-K, was filed on Feb 10, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did INCY last file an 8-K?
- On Aug 31, 2026 it covered other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 28, 2026.
- Are INCY insiders buying or selling?
- Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: CAGNONI PABLO J (President, Global Head of R&D) sold 2,642 shares on Oct 15, 2026 for $298K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has INCY made?
- 2,616 filings are on EDGAR under the registrant records that have been Incyte Corp., going back to 1994; 1,713 of them are insider ownership forms (Forms 3, 4, 5 and 144).
